John Marshall is a Rheumatology/Immunology physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
7373 Perkins Rd
Baton Rouge, LA 708084326
Telephone
225-769-4044Registry record last updated 4 Feb 2011.
Clinical trials
- An Imaging Study in ER Negative Breast Cancer by Targeting αvβ6
Sponsor: Queen Mary University of London
- Role of Active Deresuscitation After Resuscitation:
Sponsor: Unity Health Toronto
- Evaluating Novel Therapies in ctDNA Positive GI Cancers
Sponsor: Georgetown University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2019)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
42.3%Gabapentinoids6.8%Gabapentin78%Lyrica23%Part D<11 patientsSNRI6.7%Duloxetine Hcl84%Savella16%Part D<11 patients+ 8 more classes in this area
Metabolism & gastrointestinal
12.8%Proton pump inhibitor8.7%Omeprazole50%Pantoprazole Sodium25%Lansoprazole13%Esomeprazole Magnesium11%Part D<11 patientsCorticosteroid4%Prednisone100%Part D≥21 patientsCancer & immunology
10.3%Folate Analog Metabolic Inhibitor7%Methotrexate100%Part D≥39 patientsNonsteroidal Anti-inflammatory Drug3.3%Celecoxib100%Part D≥17 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”